Investor Presentation Q1 2023

99 Investor presentation First three months of 2023 Novo NordiskⓇ Potential first human dose with cell therapy in collaboration with Heartseed and others Utilise internal capabilities and disease understanding for stem cell development Accelerate innovation through partnerships Internal capabilities GMP-grade production capability my Academic collaborations Ethical stem cell practices IP positions on differentiation protocols 2 first human dose projects upcoming Therapeutic areas • iPSC derived cardiomyocyte spheroids Heartseed for direct injection into heart • Heart failure Parkinson's disease Chronic heart failure LUND Type 1 diabetes Dry age-related macular degeneration UNIVERSITY BioLamina REVOLUTIONIZING CELL CULTURE UCSF University of California San Francisco • FHD in February 2023 ● hESC derived dopaminergic progenitor neurons for placing into the brain Parkinson's disease • FHD in February 2023 • Novo Nordisk scientists embedded at UCSF lab Process development, manufacturing, QA/QC, facilities and operations at Fremont site GMP: Good manufacturing practice; IP: Intellectual property; iPSC: induced pluripotent stem cells; QA/QC: Combination of quality assurance with quality assurance and quality control; hESC: Human embryonic stem cell; FHD: First human dose

View entire presentation